MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
21.63
-0.85
-3.78%
After Hours: 21.89 +0.26 +1.20% 19:57 08/14 EDT
OPEN
22.35
PREV CLOSE
22.48
HIGH
22.39
LOW
21.29
VOLUME
1.59M
TURNOVER
--
52 WEEK HIGH
24.60
52 WEEK LOW
7.61
MARKET CAP
2.41B
P/E (TTM)
-15.1016
1D
5D
1M
3M
1Y
5Y
1D
Is Amylyx (AMLX) Quietly Rewriting Its R&D Risk‑Reward Profile As Losses Deepen Without Revenue?
Simply Wall St · 4d ago
Amylyx price target raised to $30 from $22 at BofA
TipRanks · 4d ago
Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE
NASDAQ · 4d ago
Analysts Offer Insights on Healthcare Companies: Xenon (XENE), Relay Therapeutics (RLAY) and Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 4d ago
Weekly Report: what happened at AMLX last week (0803-0807)?
Weekly Report · 4d ago
Amylyx Pharmaceuticals (AMLX) Could Be 5% Undervalued After Second Quarter Earnings
Simply Wall St · 08/07 19:46
Amylyx Pharmaceuticals: Avexitide Defines The Endocrine Rebuild
Seeking Alpha · 08/07 15:28
Amylyx price target raised to $28 from $19 at Baird
TipRanks · 08/07 11:56
More
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.